The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance. Schreiber A, Rodner F, Oberberg N, Anhlan D, et al. Antiviral Res 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.

Read + Share

Amedeo Smart

Independent Medical Education

Schreiber A, Rodner F, Oberberg N, Anhlan D, et al. The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance. Antiviral Res 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840.
PMID: 38438015